Get the Stockscreener App
25.33
0.00%
0.00
After Hours:
25.33
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.33, with a volume of 33.97M.
It is up +0.00% in the last 24 hours and down -8.09% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.33
Open:
$25.32
24h Volume:
33.97M
Relative Volume:
0.90
Market Cap:
$144.37B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.42
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-1.86%
1M Performance:
-8.09%
6M Performance:
-0.47%
1Y Performance:
+10.95%
1-Day Range:
$25.19
$25.39
1-Week Range:
$25.19
$26.10
52-Week Range:
$22.64
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.33 | 144.37B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
988.09 | 896.13B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.92 | 545.74B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
209.41 | 371.72B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.92 | 281.60B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.15 | 282.55B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Target Upgraded, Pfizer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer - GlobeNewswire Inc.
Why Pfizer Stock Still Looks Deeply Undervalued In 2026 (NYSE:PFE) - Seeking Alpha
Thrivent Financial for Lutherans Acquires 72,504 Shares of Pfizer Inc. $PFE - MarketBeat
214,779 Shares in Pfizer Inc. $PFE Purchased by North Dakota State Investment Board - MarketBeat
Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating - marketscreener.com
Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
FY2026 EPS Estimates for Pfizer Lowered by Erste Group Bank - MarketBeat
Pfizer Inc. stock (US7170811035): Q1 earnings beat, higher 2026 guidance and rich dividend yield dra - AD HOC NEWS
Pfizer Inc. stock (US7170811035): Q1 earnings beat, higher 2026 guidance and rich dividend yield in - AD HOC NEWS
Pfizer Faces Busy Week After Friday’s Drop - TechStock²
Pfizer Inc. Trade Ideas — LS:852009 - TradingView
Seagen Inc (Acquired) stock (US8166361055): what remains after the Pfizer takeover - AD HOC NEWS
How Pfizer Comirnaty Works and Where It Fits Today - AD HOC NEWS
John G Ullman & Associates Inc. Has $5.13 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan - MarketBeat
Pfizer Inc. Trade Ideas — AQUISEU:PFED - TradingView
Pfizer Inc. Trade Ideas — BX:PFEUSD - TradingView
Pfizer Inc stock (US7170811035): new trial data and pipeline focus keep attention on the pharma gian - AD HOC NEWS
Wolfe Research Says COVID Uncertainty Continues to Weigh on Pfizer (PFE) Outlook - Insider Monkey
PFE Stock Quote Price and Forecast - CNN
Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Oncology Growth Expectations - simplywall.st
Pfizer asks for emergency use of its coronavirus vaccine - The Indian Panorama
Pfizer (NYSE:PFE) Trading Down 1.7%Here's Why - MarketBeat
Pfizer Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pfizer Inc’s Next Growth Bet Is India. Investors Are Still Waiting For Proof - TechStock²
Pfizer Inc. stock (US7170811035): Q1 2026 beat, new products lift revenue while COVID business stays - AD HOC NEWS
Duavee by Pfizer, Inc - Pharmacy Times
Pfizer Refines PF-07799933 Dosing in New Phase 1 Food-Effect Study - TipRanks
Mubadala Investment dissolves share stake in Pfizer, Ford Motor, Walt Disney - marketscreener.com
Mubadala Investment Dissolves Share Stake In Pfizer, Ford Motor, Walt Disney - TradingView
Mesirow Financial Investment Management Inc. Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call - Yahoo Finance
AustralianSuper Pty Ltd Acquires 671,258 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. Stock 12‑Month Price Target Cut to $28.88, Implies 12% Upside - TradingView
PFIZER INC HUGE TARGET | PFE STOCK NEWS (jCUEslO3m8) - fathomjournal.org
Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings - Pfizer
Pfizer’s Prazosin Site-Transfer Trial Signals Quiet but Important Supply-Chain Progress - TipRanks
Pfizer stock (US7170811035): Q1 earnings beat with revenue growth and 2026 guidance - AD HOC NEWS
Jim Cramer on Pfizer: “Pfizer Does Not Have Any Earnings Momentum” - Insider Monkey
Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How - Yahoo Finance
Comirnaty COVID-19 Vaccine - AD HOC NEWS
Pfizer's Turnaround Is Taking Shape (NYSE:PFE) - Seeking Alpha
PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested? - TradingView
PFE Stock Outlook 2026: Is Pfizer a Smart Investment Right Now? - sebd.in
The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland - Yahoo Finance Singapore
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
Pfizer Hemophilia Drug Win In Europe Adds Weight To Undervalued Thesis - simplywall.st
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors - BioSpace
Get to Know Our Breakthrough Fellows! - Pfizer
An Open Letter from Pfizer Chairman and CEO Albert Bourla - Pfizer
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.07%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):